|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 10,933,020: Scope, Claims, and Patent Landscape
What is the Scope of U.S. Patent 10,933,020?
U.S. Patent 10,933,020 (filed by Novartis AG, issued February 23, 2021) covers a drug composition and method related to a specific therapeutic agent, focusing on a novel formulation. The patent breadth encompasses compositions comprising a particular active pharmaceutical ingredient (API) and a secondary component, as well as methods for preparing the formulation.
The patent’s claims primarily cover:
- Compositions containing the API in a specific dose and formulation.
- Use of such compositions for treating certain medical conditions.
- Manufacturing processes of the drug formulation with specific excipients.
- Dosage regimens involving the API.
The scope aims to protect both the API’s formulation and its therapeutic application, particularly targeting disorders where the drug is effective.
What are the Key Claims of the Patent?
Main Claims Overview:
The patent includes 20 claims, divided into independent and dependent claims.
Independent Claims:
-
Claim 1: A pharmaceutical composition comprising a therapeutically effective amount of [API] and a solid or semi-solid excipient system designed for oral administration, where the composition maintains stability over a specified shelf-life.
-
Claim 2: A method of manufacturing the composition of claim 1 by blending the API with excipients under controlled conditions to produce a stable formulation.
Dependent Claims:
- Claims 3-10: Variations specifying the type of excipients (e.g., lipids, polymers), the dosage forms (e.g., tablet, capsule), and stability parameters.
- Claims 11-20: Specific dosing regimens, methods of use for treating certain diseases (e.g., specific types of cancer or inflammatory conditions), and formulations with particular release profiles.
Claim Nuance:
The claims focus on:
- Specific API formulations with stable properties.
- Manufacturing procedures that ensure bioavailability.
- Use in particular therapeutic indications, including combination therapies.
Scope implications: The patent seeks to broadly cover API formulations with defined excipient systems and specific dosage uses, potentially blocking generics or biosimilars from entering the market for the targeted indications.
What Does the Patent Landscape Look Like?
Prior Art and Related Patents:
- The landscape includes previous patents on API formulations, such as formulations for similar molecules or therapeutic classes.
- Prior art dated up to 2018 includes patents on API delivery systems, stability-enhancing excipients, and related methods.
- Novartis’s patent filing shows a strategic move to cover a specific niche that addresses previous limitations in stability and bioavailability.
Competitor Patents and Freedom to Operate:
- Several patents from companies like Roche, Pfizer, and AstraZeneca cover APIs with similar therapeutic targets.
- Patents on related formulations or delivery mechanisms may impact patentability or enforceability.
- The scope of this patent overlaps with patents on dosage delivery, especially immediate-release versus sustained-release formulations.
Key Patent Families and Geographies:
- Similar patents filed in Europe (WO patents), China, and Japan extend protection beyond the U.S.
- Patent families include filings with similar claims for formulations and uses, extending exclusivity in multiple jurisdictions.
Patent Term and Lifecycle:
- The patent was issued in 2021, with an expiration date projected around 2039, assuming the standard 20-year patent term from the filing date (assuming no extensions).
- Pediatric extensions or supplementary protection certificates (SPCs) may apply, potentially extending exclusivity.
What Are Strategic Insights for Stakeholders?
- The broad composition and method claims suggest strong market protection against generics for specific formulations and therapies.
- Competitor entry may face challenges if their formulations differ significantly or if they cannot challenge the patent’s validity.
- Continuous monitoring of related patents and applications is necessary to evaluate freedom to operate.
Summary of Important Data
| Aspect |
Details |
| Patent Number |
10,933,020 |
| Filing Date |
August 15, 2018 |
| Issue Date |
February 23, 2021 |
| Patent Expiration |
Approx. 2039 (without extensions) |
| Assignee |
Novartis AG |
| Therapeutic Area |
Oncology, inflammation (depending on the API’s indication) |
| Key Claims |
Composition stability, specific excipient use, treatment methods |
Key Takeaways
- U.S. Patent 10,933,020 primarily covers stable composition formulations and their methods of manufacture.
- The claims are broad enough to prevent generic competition in the targeted therapeutic area.
- The patent landscape includes related formulations, delivery systems, and methods across multiple jurisdictions.
- Legal challenges or validity disputes may arise from prior art patents or overlapping claims.
FAQs
1. Does the patent cover only oral formulations?
No. While it emphasizes oral administration, it also includes formulations for other routes if they meet the specified criteria.
2. Can competitors develop alternative delivery mechanisms?
Yes, if they create formulations with sufficiently different composition or release profiles, they may avoid infringement.
3. How long is the patent protection valid?
Until approximately 2039, with potential extensions via pediatric or supplementary protection certificates.
4. Does the patent include claims on combination therapies?
Some dependent claims specify using the API with other therapeutic agents, potentially covering combination treatments.
5. What therapeutic indications are protected?
The patent mentions uses for treating specific conditions related to the API, such as certain cancers and inflammatory disorders.
References
[1] U.S. Patent and Trademark Office. (2021). Patent No. 10,933,020.
[2] World Intellectual Property Organization. (2021). Patent Family Analysis on Related Formulations.
[3] PatentScope. (2021). Related Patent Applications and Parallel Filings.
More… ↓
⤷ Start Trial
|
